Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for BioRestorative Therapies (BRTX) over the last 12 years, with Q1 2025 value amounting to $36400.0.

  • BioRestorative Therapies' Capital Expenditures rose 2446.15% to $36400.0 in Q1 2025 from the same period last year, while for Sep 2025 it was $48834.0, marking a year-over-year decrease of 7018.3%. This contributed to the annual value of $106189.0 for FY2024, which is 3791.68% down from last year.
  • Per BioRestorative Therapies' latest filing, its Capital Expenditures stood at $36400.0 for Q1 2025, which was up 2446.15% from $12434.0 recorded in Q4 2024.
  • Over the past 5 years, BioRestorative Therapies' Capital Expenditures peaked at $137674.0 during Q2 2022, and registered a low of -$24605.0 during Q3 2022.
  • In the last 4 years, BioRestorative Therapies' Capital Expenditures had a median value of $36400.0 in 2025 and averaged $44527.3.
  • The largest annual percentage gain for BioRestorative Therapies' Capital Expenditures in the last 5 years was 38927.85% (2024), contrasted with its biggest fall of 8224.32% (2024).
  • Over the past 4 years, BioRestorative Therapies' Capital Expenditures (Quarter) stood at $42581.0 in 2022, then surged by 64.45% to $70024.0 in 2023, then crashed by 82.24% to $12434.0 in 2024, then soared by 192.75% to $36400.0 in 2025.
  • Its Capital Expenditures was $36400.0 in Q1 2025, compared to $12434.0 in Q4 2024 and $58459.0 in Q3 2024.